English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16714/19009 (88%)
Visitors : 5697974      Online Users : 53
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27597


    標題: Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation
    作者: Lin, Ching-Yih
    Tian, Yu-Feng
    Wu, Li-Ching
    Chen, Li-Tzong
    Lin, Li-Ching
    Hsing, Chung-Hsi
    Lee, Sung-Wei
    Sheu, Ming-Jen
    Lee, Hao-Hsien
    Wang, Yu-Hui
    Shiue, Yow-Ling
    Wu, Wen-Ren
    Huang, Hsuan-Ying
    Hsu, Han-Ping
    Li, Chien-Feng
    Chen, Shang-Hung
    Chen, Li-Tzong�
    貢獻者: 保健營養系
    關鍵字: Chromatin Remodeling Factor
    Preoperative Radiotherapy
    Sphincter Preservation
    Functional-Analysis
    Tumor Response
    Acute Toxicity
    Dna-Damage
    Carcinoma
    Overexpression
    Survival
    日期: 2012-08
    上傳時間: 2014-03-21 16:14:44 (UTC+8)
    出版者: Bmj Publishing Group
    摘要: Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT.Methods Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival.Results Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced post-treatment tumour status (T3, T4, p<0.001) and inferior tumour regression grade (p=0.028). Of note, high-expression of Rsf-1 emerged as an adverse prognosticator for diseases-specific survival (p=0.0092) and significantly predicted worse MeFS (p=0.0006). Moreover, high-expression of Rsf-1 also remained prognostic independent for worse MeFS (HR 2.834; p=0.0214).Conclusions High-expression of Rsf-1 is associated with poor therapeutic response and adverse outcome in rectal cancer patients treated with neoadjuvant CRT, which confers tumour aggressiveness and therapeutic resistance through chromatin remodelling and represents a potential prognostic biomarker in rectal cancer.
    關聯: Journal of Clinical Pathology, 65(8), 687-692
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML287View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback